Investigation Report on China Adefovir Market, 2010-2019
In Mar. 2015, WHO issued Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection, indicating that 2 billion people around the world had or are having HBV infection and that about 240 million people are infected with chronic hepatitis B virus (HBV), among which 0.65 million die of hepatitis B-related diseases. Hepatitis B surface antigen (HBsAg ) rate among people aged below 60 has fallen from 9.75% a decade ago to 7.18% now. However, since China has a large population base, the number of people infected with chronic HBV is calculated to be over 90 million and the number of chronic hepatitis B (CHB) patients is 20 million. Hence, the severe status of diagnosis and treatment of CHB. So far, chronic and viral hepatitis B has become one of the major threats to human health and CHB has already become the ninth leading cause of death.
Nucleotide analog, the leading antiviral product for the treatment of CHB, has such main varieties as entecavir, adefovir dipivoxil, lamivudine, telbivudine, emtricitabine and tenofovir disoproxil in the clinic.
In 2002, GlaxoSmithKline (GSK) acquired the franchise rights to market adefovir dipivoxil, the anti-hepatitis B drug of Gilead Sciences, Inc. in mainland China, Japan, Korea and Taiwan under the trade name of Hepsera. In 2013, the global sales value of Hepsera was down by 23.81%. In 2005, adefovir dipivoxil made by GSK was first approved to enter China under the trade name of Hepsera.
Adefovir develops fast after entering China, annual sales value rising from about CNY 10 million in 2005 to CNY 400 million in 2013 and CAGR reaching nearly 60% during the period of 2005-2014. GlaxoSmithKline (Tianjin) Co., Ltd, United Laboratories, Fujian Cosunter Pharmaceutical Co., Ltd and Chia Tai Tianqing Pharmaceutical Group Co., Ltd occupy the majority of the Chinese market, among which GlaxoSmithKline (Tianjin) Co., Ltd had the largest market share of about 43% for sales value in 2014.
With the large amounts of hepatitis B patients in China, the market size of adefovir is expected to keep growing in the next few years.
Readers can get at least the following information from this report:
market size of adefovir in China
competitive landscape of adefovir in Chinese market
price of adefovir made by different enterprises in China
market outlook of adefovir in China
suggests the following groups of people purchase this report:
manufacturers of anti-hepatitis drugs
investors/ research institutions interested in Chinese medicine market
any interest in the Chinese medicine market, please contact CRI for customized survey service
Chia Tai Tianqing Pharmaceutical Group Co., Ltd; TIPR Pharmaceutical Responsible Co., Ltd; United Laboratories; Fujian Cosunter Pharmaceutical Co., Ltd; GlaxoSmithKline (Tianjin) Co., Ltd